Spiralling healthcare costs leave consumers exposed to out-of-pocket hospitalisation expenses not covered by medical aid
Teresa Settas • June 30, 2020
With healthcare costs growing at around 10% - levels well-beyond inflation - and with most medical schemes announcing annual plan increases of between 8-9% for 2020, South African medical scheme consumers are left with little choice but to buy down on their medical scheme benefit options in a bid to manage their high living costs. Exacerbating healthcare costs and utilisation of medical scheme benefits is the increasingly unhealthy lifestyles of South Africans leading to chronic diseases such as heart disease, diabetes, hypertension and even certain cancers.
The buy-down in medical benefit options has a commensurate reduction in the benefits covered and limits offered, which many South Africans don’t realise until they’re faced with an unexpected and unaffordable bill for in-hospital treatment not covered under their benefit option. This has thrown the spotlight on the critical need for Gap Cover insurance to ensure that consumers are not slapped with onerous out of pocket expenses for in-hospital treatments as they contemplate migrating to more affordable, lower medical scheme benefit options.
“The reality is that medical scheme cover can cost 20% or more of monthly disposable household income. If you consider the hyper-inflationary growth in healthcare costs, the annual medical scheme increases of 8-10%, and the fact that salary increases have declined to lows of 3-4% annually, if at all, it is clear that medical schemes costs are eating into a much greater share of monthly household income than ever before. Given the disastrous state of the public healthcare system, private healthcare is an expensive but essential safety net that consumers who can afford it understandably do not want to live without,” explains Martin Rimmer, CEO of Sirago Underwriting Managers, a leading provider of Gap Cover Solutions, underwritten by GENRIC Insurance Company Limited.
“Cheaper medical scheme options provide less benefits and more restrictions related to accessing benefits. Buying down could leave you exposed to onerous out of pocket expenses if you don’t have Gap Cover to protect you from shortfalls that exist between the agreed medical scheme rate and the rate that the healthcare provider charges. In fact, even on comprehensive options, shortfalls still exist as a shortage of specialist skills and lack of supply side regulation on pricing means that healthcare providers determine their own fees, which typically falls well beyond medical schemes rates,” adds Rimmer.
Gap insurance covers the difference that arises from the rate that specialists charge for in-hospital procedures – which are often as high as 300% to 500% higher than the rate paid by your medical scheme. For example, if your medical scheme option only pays out at 100% of tariff, you will then be liable to pay the shortfall of the other 200% to 400% charged by your healthcare provider as an “out of pocket” expense. This difference could cost tens of thousands of Rands to a medical scheme member without Gap Cover.
These shortfalls occur in several ways including:
- Surgeons, anaesthetists and other specialists charge more than the contracted / agreed rate with your medical scheme for certain in-hospital procedures;
- Your medical scheme applies co-payments or deductibles on certain in-hospital admissions and or procedures;
- Certain expensive in-hospital items and appliances have annual sub-limits, for example the internal prosthetic devices used in a joint replacement procedure.
While consumers increasingly move to more affordable ‘core hospital plans’, adding gap insurance to cover any potential in-hospital tariff shortfalls is essential to protect you from big financial expenses related to shortfalls on in-hospital treatment, from the anaesthetist to the specialist surgeon. It is important to point out that Gap Cover is designed to cover you for shortfalls on in-hospital treatment and procedures and does not cover day-to-day medical expenses for GP visits, dentistry, optometry and the like.
“Most consumers don’t fully realise just how serious these shortfalls can be, and the financial repercussions are onerous, if not crippling. Sirago is seeing an increase of beneficiaries reaching their overall annual claims limit within a 12-month period and has already experienced a single hospital event resulting in this limit being reached. In one month, Sirago has processed multiple claims larger than R40 000 each to the value of R1 300 000 in tariff shortfalls not covered by Medical Schemes that clients would have had to pay from their own pockets, had they not had Gap insurance in place. There are very few people who can manage this kind of financial impact without taking additional Gap Cover. Given the financial exposure, not supplementing your medical scheme benefits with a Gap Cover policy could be a very costly mistake.
Gap Cover is an Affordable Essential
When you consider the potential financial quantum of a shortfall on your medical scheme benefits, and that a gap premium is around R370 per month (2020 Sirago Gap Plus) and each family member is covered for up to a maximum of R164 000 per annum, it is clearly evident that Gap Cover policies are a critical part of an individual or corporate employers strategy to insure against medical scheme shortfalls at a cost effective monthly premium.
On a closing note, Rimmer advises consumers to always negotiate the pricing of any planned surgery with healthcare providers before and ask for a formal quote from all the medical role players. That way there are no surprises or unexpected costs creeping in after the fact that you would find difficult to dispute, unless there were specific complications during the procedure. Finally, be wary of doctors asking you upfront whether you have gap cover or not – overbilling based on a client’s insurance portfolio is a growing unethical practice by some unscrupulous medical specialists looking to capitalise on the patient’s insurance cover by overcharging, knowing that the patient has the insurance to cover the inflated price,” concludes Rimmer.
A major health event such as surgery in hospital is usually an unpredictable event and can strike a family at any time. An accident, heart attack, spinal injuries, time spent in ICU and cancer - one of the current top high claims causes - can leave families financially destitute and in a crisis if they do not have the financial means to cover these shortfalls. Consumers are mainly at risk when it comes to in-hospital treatment where shortfalls of R30 000 to R40 000 are the norm and no longer the exception. The need for Gap Cover and Co-payment Cover as an insured solution is critical in the future of the average consumer’s personal healthcare planning in South Africa.
Sirago is an authorised financial service provider (FSP 4710), a leading provider of Gap Cover Solutions underwritten by GENRIC Insurance Company Limited (FSP 43638), an Authorised Financial Services Provider and registered Short-Term insurer.
Note:
The content of this article does not constitute financial advice. For more information go to www.sirago.co.za
(T’s & C’s apply).
Dr Michael de Villiers explains why people can become sick every flu season and why the influenza vaccine is generally recommended every year.
Colorectal cancer, one of the most prevalent yet preventable cancers, can develop in the colon or rectum, often starting as small polyps that can quietly become malignant if left unchecked. Dr Mpho Ramabulana, a colorectal surgeon and gastroenterologist at Netcare Akasia Hospital, underscores the life-saving power of vigilance and the importance of early detection.
Cardiologist Dr Robert Routier urges the public to check their personal risk factors regularly to help prevent or manage cardiovascular disease.
The physical strain pregnancy puts on an expectant mother’s body should not be underestimated. An obstetrician gynaecologist offers her insights for alleviating discomfort and promoting wellbeing with exercise and stretching throughout pregnancy.
Dr Patience Sigwadi, a leading paediatric nephrologist practising at Netcare Unitas Hospital in Centurion, has issued an urgent call for increased focus on skills development to address the escalating kidney disease crisis among children in South Africa.
Paediatric Nephrologist Professor Bhimma was recently awarded the Fellowship to acknowledge his extensive work in research, community-based outreach and teaching of paediatric nephrology, among others.
Netcare congratulates Professor Bhekifa Dube on his invitation to join the European Society for Vascular Surgery's clinical practice guidelines committee. His selection as the only specialist from the continent highlights the significance of this achievement on the global stage.
The lives of millions of South Africans with a litany of rare diseases can be vastly improved, and even saved, by addressing challenges in identifying, studying and treating their conditions. With Rare Disease Day on the 28th of February 2025, the Rare Diseases Access Initiative (RDAI) is driving an evolution of the country’s healthcare, through innovative strategies to better care for over 4.2million people living with an estimated 7000 rare diseases. “As our healthcare system faces significant changes in the years ahead, it is vital that we also advocate for people living with rare diseases in South Africa, especially those with limited healthcare access,” said Kelly du Plessis, CEO of Rare Diseases South Africa (RDSA), a member of RDAI. “As part of our ongoing research and awareness efforts, RDAI has conducted an initial analysis of the incidence and prevalence of rare diseases within the country.” This research will assist in improving access to healthcare, policy development, and patient advocacy, while giving critical insight into the challenges faced by patients. “According to research, some rare diseases affect fewer than 1 in a million people, while others, such as Down syndrome, cystic fibrosis, and haemophilia, have a more recognisable prevalence,” says Dr. Helen Malherbe, RDAI lead researcher on rare disease prevalence data. “Many conditions are undetected, underdiagnosed or misdiagnosed, with too many having no information available about them at all.” The RDAI was formed in 2019 to promote a more favourable environment for those impacted by rare diseases in South Africa. Participants include Ampath, the Board of Healthcare Funders (BHF), Discovery Health, Genetic Counsellors South Africa (SASHG), the Government Employees Medical Scheme (GEMS), Health Funders Association (HFA), Medihelp, Medscheme, North-West University (NWU), Rare Diseases South Africa (RDSA), the South African Medical Association (SAMA) and The South African Medical Technology Industry Association (SAMED). The Council for Medical Schemes (CMS) participates as an observer. In the same year, Rare Disease International signed a memorandum of understanding with the World Health Organisation leading to an international rare disease policy framework. In 2021, the United Nations General Assembly moved to adopt a resolution recognising 300 million people living with rare diseases worldwide. “A general lack of awareness and delayed diagnosis remain major hurdles for those affected by rare diseases. Policymakers and healthcare stakeholders need to prioritise access to treatment, diagnosis, and support for rare disease patients,” says Bada Pharasi, CEO of IPASA, “Through this initiative, working collaboratively with stakeholders at every level of the healthcare supply chain, we can bring real and meaningful change to those affected, including family members and care givers, through smart and efficient strategies.” The globally agreed definition of a rare disease is any medical condition with a specific pattern of clinical signs, symptoms, and findings that affects fewer than or equal to 1 in 2000 persons in a population. “Most are genetic, and some are inherited and passed down in families,” Malherbe says. “Some affect only the patient’s genetic recipe, while others may be acquired during life due to infection, trauma, or environmental effects. For many, the cause is still unknown. “These conditions mainly affect children, as they are largely incurable and many are life-threatening. Some require specialised and co-ordinated care, some have limited and expensive treatment options, while others have no information or effective treatments at all,” she adds. The RDAI is calling for a patient-centred care model built on equitable access, transparency and efficiency. Naturally, this model calls for the open participation of patients, the healthcare industry, health professionals, and the Government. “The most critical elements are robust diagnosis standards, improved access to treatment, data collection and management, co-ordination of care, measurement of outcomes and ongoing collaborative research,” du Plessis says. “We need to establish rare disease advisory committees, map gaps and opportunities, establish system requirements, create a roadmap and plan a phased implementation with clear timelines.” The RDAI states that these policy development steps would be a start in quantifying the disease burden and defining standards of care. This would be followed by building and strengthening the capacity to facilitate appropriate diagnosis, treatment, continuity and data monitoring. Thoneshan Naidoo, Chief Executive Officer of the Health Funders Association noted that, “We appreciate the unique opportunity provided by RDAI which enables stakeholders across the industry to work together and identify strategies that improve equitable access to the appropriate diagnosis, treatment and healthcare services for rare disease patients, in an affordable and sustainable manner, taking account of the other pressing needs across the healthcare system.” “True innovation in healthcare is only possible through partnerships and joint advocacy efforts that raise awareness and improve access to treatment. Our long-term goal is the development of a rare diseases policy framework and guidelines for coordinated care,” says Pharasi. “Our members are united in the commitment to unlocking improved patient outcomes and improving access to services and robust health needs assessment facilities.” he concludes. About RDAI The Rare Diseases Access Initiative (RDAI) is dedicated to advocating for improved healthcare access, policy development, and patient support for those affected by rare diseases in South Africa. The initiative brings together key healthcare stakeholders, including pharmaceutical associations, funders, genetic specialists, and patient advocacy groups, to drive impactful change. About RDSA Founded in 2013, Rare Diseases South Africa (RDSA) is a non-profit organisation advocating to ensure that people living with rare diseases and congenital disorders experience greater recognition, support, improved health service and better overall quality of life. Started out of personal need following the diagnosis of organisation founder, Kelly du Plessis' son, it became evident that there was a lack of awareness and support for rare diseases in general in South Africa. About IPASA The Innovative Pharmaceutical Association South Africa (IPASA) is a voluntary trade association representing 24 leading pharmaceutical companies committed to research, development, and innovation. Our mission is to drive healthcare advancement by advocating for policies that improve patient access to safe, high-quality, and affordable medicines.
Gastroenterologist Dr. Barbara Makumbi discusses common risk factors and offers tips for managing reflux and the longer-term condition known as gastroesophageal reflux disease (GORD).
From treating trauma injuries caused by wildlife, road accidents and sports, to heart attacks, stroke, or the sudden onset of other concerning medical symptoms – the emergency department at Netcare St Anne’s Hospital never sleeps.
